Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A person who has been diagnosed with acute coronary syndrome and is to undergo a percutaneous coronary intervention.~* A person who is of the legal age of 18 and is mentally competent to provide a signed written informed consent.~* If a woman is of childbearing potential (i.e., before menopause), she must test negative for pregnancy and agree to use a reliable method of birth control.~Exclusion Criteria:~* A person who has had an ischemic stroke within the last 3 months or a hemorrhagic stroke at any time in the past.~* A person who has active internal bleeding or has a history of a bleeding disorder.~* Individuals who are at an increased risk of bleeding based on laboratory criteria evaluated by the treatment physician or on medication that can cause bleeding.~* A person who has liver disease; for example, cirrhosis.~* A person who has a condition such as alcoholism, mental illness, or is drug dependent.~* A person who has cardiogenic shock, a refractory ventricular arrhythmia, or congestive heart failure (class IV).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prasugrel (Type: EXPERIMENTAL): Oral loading dose of six 10 mg prasugrel tablets and four placebo tablets matched to clopidogrel, followed by an oral maintenance dose of prasugrel one 10 mg tablet and one placebo tablet matched to clopidogrel once daily
- Clopidogrel (Type: ACTIVE_COMPARATOR): Oral loading dose of four 75 mg clopidogrel tablets and six placebo tablets matched to prasugrel, followed by an oral maintenance dose of one 75 mg clopidogrel tablet and one placebo tablet matched to prasugrel once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).